Search

Displaying results 6591 - 6600 of 10000 in total
  1. Drug

    MIV-701

    go.drugbank.com/drugs/DB05736
    Experimental

    MIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis.

  2. Drug

    FK352B

    go.drugbank.com/drugs/DB06484
    Experimental

    FK352B is a adenosine A1 antagonist that is developed for the treatment of dialysis-induced hypotension.

    Synonyms: 2-((2R)-1-((2E)-3-(2-PHENYLPYRAZOLO(1,5-A)PYRIDIN-3-YL)PROP-2-ENOYL)PIPERIDIN-2-YL)ACETIC ACID, 2-PIPERIDINEACETIC ACID, 1-((2E)-1-OXO-3-(2-PHENYLPYRAZOLO(1,5-A)PYRIDIN-3-YL)-2-PROPEN-1-YL)-, (2R)-
  3. Drug

    CMC 001

    go.drugbank.com/drugs/DB05353
    Investigational

    CMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.

  4. Drug

    Perflubron

    go.drugbank.com/drugs/DB05791
    Investigational

    Perflubron (Oxygent) is being developed as an intravascular oxygen carrier designed to augment oxygen delivery in surgical patients.

  5. Drug

    Olmutinib

    go.drugbank.com/drugs/DB13164
    Investigational

    Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer. … Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016.

    Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
  6. Drug

    Sibrotuzumab

    go.drugbank.com/drugs/DB06474
    Investigational

    It is used to treat cancer.

  7. Drug

    Vicriviroc

    go.drugbank.com/drugs/DB06652
    Investigational

    Vicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1. … This pyrimidine based drug inhibits the interaction of HIV-1 with CCR5, preventing viral entry into cells. This drug was developed by Schering-Plough.

  8. Drug

    RDP58

    go.drugbank.com/drugs/DB06566
    Experimental

    RDP58 (NH2-arg-norleucine (nle)-nle-arg-nle-nle-nle-gly-tyr-CONH2) (Sangstat Corp., Fremont, California) is a novel synthetic peptide that inhibits early signal transduction pathways for the expression

  9. Drug

    AG-702

    go.drugbank.com/drugs/DB05836
    Experimental

    This drug is developed by antigenics for the treatment of genital herpes infection and is under phase I of clinical trial. … HSPs are present in all cells in all life forms from bacteria to mammals, and their structure and function are similar across these diverse life forms.

  10. Drug

    Tosatoxumab

    go.drugbank.com/drugs/DB16557
    Investigational

    by protecting against destruction of host cells mediated by the toxin. … Tosatoxumab is a fully-human monoclonal antibody (IgG1λ) targeting the Staphylococcus aureus alpha-toxin or the S. aureus alpha-hemolysin[A191829, L31568, L31573] and thereby preserving human immune cells